MedPath

The Effect of Vocal Rest Versus Vocalization Following Xeomin® Injections in Spasmodic Dysphonia

Not Applicable
Conditions
Adductor Spasmodic Dysphonia
Registration Number
NCT03129087
Lead Sponsor
Lawson Health Research Institute
Brief Summary

This study will compare the effects of vocal rest versus continuous vocalization for one hour immediately following botulinum toxin injections for adductor spasmodic dysphonia.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Diagnosed with adductor spasmodic dysphonia (ADSD) by an experienced neurologist and otolaryngologist. ADSD patients who have been stabilized on their treatment dose for at least 2 treatment cycles.
Exclusion Criteria
  • Diagnosed with another neurological disorder that is combined with ADSD (i.e. Parkinson's disease and ADSD). Previous history of an additional vocal pathology (i.e. vocal polps, vocal nodules, unilateral vocal fold paralysis, etc.)

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Severity of spasmodic dysphonia symptomsSix weeks post-treatment

Acoustic measures and perceptual ratings of vocal spasm severity

Patient-reported outcome measures of symptoms and communicationsix weeks post-treatment

Six patient-reported questionnaires related to symptoms, communication effectiveness, quality of life, and self-efficacy

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

LawsonHRI

🇨🇦

London, Ontario, Canada

LawsonHRI
🇨🇦London, Ontario, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.